These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

143 related items for PubMed ID: 26923729

  • 1. Treatments for post-menopausal osteoporotic women, what's new? How can we manage long-term treatment?
    Herrero S, Pico Y.
    Eur J Pharmacol; 2016 May 15; 779():8-21. PubMed ID: 26923729
    [Abstract] [Full Text] [Related]

  • 2. Management of postmenopausal osteoporosis and the prevention of fractures.
    Gambacciani M, Levancini M.
    Panminerva Med; 2014 Jun 15; 56(2):115-31. PubMed ID: 24942322
    [Abstract] [Full Text] [Related]

  • 3. Denosumab, a new pharmacotherapy option for postmenopausal osteoporosis.
    Josse R, Khan A, Ngui D, Shapiro M.
    Curr Med Res Opin; 2013 Mar 15; 29(3):205-16. PubMed ID: 23297819
    [Abstract] [Full Text] [Related]

  • 4. Denosumab and teriparatide transitions in postmenopausal osteoporosis (the DATA-Switch study): extension of a randomised controlled trial.
    Leder BZ, Tsai JN, Uihlein AV, Wallace PM, Lee H, Neer RM, Burnett-Bowie SA.
    Lancet; 2015 Sep 19; 386(9999):1147-55. PubMed ID: 26144908
    [Abstract] [Full Text] [Related]

  • 5. How to manage postmenopausal osteoporosis?
    Body JJ.
    Acta Clin Belg; 2011 Sep 19; 66(6):443-7. PubMed ID: 22338309
    [Abstract] [Full Text] [Related]

  • 6. New approaches to pharmacological treatment of osteoporosis.
    Akesson K.
    Bull World Health Organ; 2003 Sep 19; 81(9):657-64. PubMed ID: 14710507
    [Abstract] [Full Text] [Related]

  • 7. [Treatment of post-menopausic osteoporosis: what's new in 2014?].
    Reginster JY, Neuprez A, Lecart MP, Sarlet N, Distèche S, Bruyère O.
    Rev Med Liege; 2014 Sep 19; 69(7-8):441-53. PubMed ID: 25158386
    [Abstract] [Full Text] [Related]

  • 8. Cost-effectiveness of denosumab in the treatment of postmenopausal osteoporosis in Canada.
    Chau D, Becker DL, Coombes ME, Ioannidis G, Adachi JD, Goeree R.
    J Med Econ; 2012 Sep 19; 15 Suppl 1():3-14. PubMed ID: 23035625
    [Abstract] [Full Text] [Related]

  • 9. Osteoporosis management in post-menopausal women.
    Christenson ES, Jiang X, Kagan R, Schnatz P.
    Minerva Ginecol; 2012 Jun 19; 64(3):181-94. PubMed ID: 22635014
    [Abstract] [Full Text] [Related]

  • 10. A new antiresorptive approach to the treatment of fragility fractures: long-term efficacy and safety of denosumab.
    Tarantino U, Celi M, Feola M, Liuni FM, Resmini G, Iolascon G.
    Aging Clin Exp Res; 2013 Oct 19; 25 Suppl 1():S65-9. PubMed ID: 24046047
    [Abstract] [Full Text] [Related]

  • 11. Bisphosphonates for prevention of postmenopausal osteoporosis.
    Ravn P.
    Dan Med Bull; 2002 Feb 19; 49(1):1-18. PubMed ID: 11894721
    [Abstract] [Full Text] [Related]

  • 12. The effect of 8 or 5 years of denosumab treatment in postmenopausal women with osteoporosis: results from the FREEDOM Extension study.
    Papapoulos S, Lippuner K, Roux C, Lin CJ, Kendler DL, Lewiecki EM, Brandi ML, Czerwiński E, Franek E, Lakatos P, Mautalen C, Minisola S, Reginster JY, Jensen S, Daizadeh NS, Wang A, Gavin M, Libanati C, Wagman RB, Bone HG.
    Osteoporos Int; 2015 Dec 19; 26(12):2773-83. PubMed ID: 26202488
    [Abstract] [Full Text] [Related]

  • 13. Osteoporosis treatment and prevention for postmenopausal women: current and future therapeutic options.
    Pinkerton JV, Thomas S, Dalkin AC.
    Clin Obstet Gynecol; 2013 Dec 19; 56(4):711-21. PubMed ID: 24100598
    [Abstract] [Full Text] [Related]

  • 14. The inhibition of RANK-ligand in the management of postmenopausal osteoporosis and related fractures: the role of denosumab.
    Capozzi A, Lello S, Pontecorvi A.
    Gynecol Endocrinol; 2014 Jun 19; 30(6):403-8. PubMed ID: 24592987
    [Abstract] [Full Text] [Related]

  • 15. Spotlight on denosumab in postmenopausal osteoporosis.
    Moen MD, Keam SJ.
    BioDrugs; 2011 Aug 01; 25(4):261-4. PubMed ID: 21815702
    [Abstract] [Full Text] [Related]

  • 16. Bisphosphonates for post-menopausal osteoporosis: are they all the same?
    Rizzoli R.
    QJM; 2011 Apr 01; 104(4):281-300. PubMed ID: 21258058
    [Abstract] [Full Text] [Related]

  • 17. Role of RANK ligand and denosumab, a targeted RANK ligand inhibitor, in bone health and osteoporosis: a review of preclinical and clinical data.
    Dempster DW, Lambing CL, Kostenuik PJ, Grauer A.
    Clin Ther; 2012 Mar 01; 34(3):521-36. PubMed ID: 22440513
    [Abstract] [Full Text] [Related]

  • 18. New developments in the treatment of osteoporosis.
    Eriksen EF, Halse J, Moen MH.
    Acta Obstet Gynecol Scand; 2013 Jun 01; 92(6):620-36. PubMed ID: 22646526
    [Abstract] [Full Text] [Related]

  • 19. [Update on treatment of postmenopausal osteoporosis].
    Body JJ.
    Rev Med Brux; 2008 Sep 01; 29(4):301-9. PubMed ID: 18949981
    [Abstract] [Full Text] [Related]

  • 20. New management options for osteoporosis with emphasis on SERMs.
    McClung MR.
    Climacteric; 2015 Sep 01; 18 Suppl 2():56-61. PubMed ID: 26503459
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 8.